DNER and cancer: Taken together, these results suggest that both BET activity and eRNA expression are necessary to drive cMYC transcription in cancers expressing CCAT1 and propose that CCAT1 is a novel diagnostic biomarker for identifying patients who are likely to benefit from BET inhibitors.